PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

NEW YORK CITY, NY / ACCESS Newswire / March 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

What is the Purpose of Cancer Clinical Trials? 2. What is the Role of Clinical Trials in Cancer Treatment, Including Risks ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Hesham Abdullah, GSK's Senior Vice President, Global Head Oncology R&D, stated, "This acquisition adds to GSK's growing pipeline of targeted therapeutics for cancers originating in the ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...